www.esmo.org

Wir starten im Herbst noch fünf weitere Studien, alle Informationen und laufenden Studien finden Sie in der Rubrik „Studienzentrale“

EmpowHER:
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence

Elegant:
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence

MK-010:
Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

Erika:
Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer: An open-label, two-arm, randomized, phase II study of elacestrant plus ribociclib vs. AI (plus GnRH agonist in pre-/perimenopausal women and men) plus ribociclib as neoadjuvant therapy for endocrine-responsive HER2-negative early breast cancer

Artillery:
Artillery-CarDI, Artificial Intelligence for early detection of non-communicable disease risk in people with breast cancer

CapiCorn:
An interventional, open-label, phase III study to evaluate the safety, efficacy, and impact on quality of life of capivasertib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer and progression on prior endocrine-based treatment

Bei Fragen wenden Sie sich, am besten per Email, direkt an die Studienzentrale:
studienzentrale-frauenklinik@med.uni-muenchen.de